Allena Pharmaceuticals (NASDAQ:ALNAQ – Get Rating) is set to announce its earnings results on Tuesday, November 8th.
Allena Pharmaceuticals Stock Performance
Shares of Allena Pharmaceuticals stock remained flat at $0.01 on Monday. The stock had a trading volume of 363,247 shares, compared to its average volume of 12,972,626. The company's 50-day moving average is $0.02. Allena Pharmaceuticals has a 12 month low of $0.01 and a 12 month high of $1.00.
Get Allena Pharmaceuticals alerts:About Allena Pharmaceuticals
(Get Rating)
Allena Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease.Read More
- Get a free copy of the StockNews.com research report on Allena Pharmaceuticals (ALNAQ)
- Bulls Vs Bears: Mullen Automotive Short Interest Grows
- Palantir Falls Into The Hands Of Value Investors
- The Analysts Can't Keep Up with Arista Networks Stock
- 3 Reasons Amazon Will Deliver Better 2023 Returns
- A Turnaround is Brewing in Starbucks Stock
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
